Background: Stereotactic ablative radiotherapy (SABR) is a treatment option for patients with early stage non-small cell lung cancer (NSCLC) and recurrent or oligometastatic disease who are not surgical candidates. Due to the continuous motion of tumors within the lungs, implementing a strategy to track the target lesion is crucial. One method is to place fiducial markers which the robotic SABR system is able to track during treatment. However, placing these markers in a manner that maximizes tracking efficacy can be challenging. Using a novel fiducial placement guidance system (FPGS) during fiducial deployment may offer a way to improve the quantity of fiducials tracked by the robotic SABR system.
Method: This was an institutional, retrospective review identifying all patients who received robotic SABR for lung tumors from May 2015 until January 2017. The FPGS was instituted in May 2016. The median number of fiducials tracked and the rate of complication was compared between patients whose fiducials were placed using FPGS versus those that were not.
Results: A total of 128 patients with 147 treated lung lesions were identified. Of the lesions that utilized FPGS (n = 44), 28 had 2 tracked fiducials (63.6%), 14 had 3 (31.8%) and 2 had 4 (4.6%). Of the lesions treated without FPGS (n = 103), 5 had 1 tracked fiducial (4.9%), 91 had 2 (88.4%), 6 had 3 (5.8%), and 2 had 4 (1.9%). A significant improvement in the median number of fiducials tracked per fraction was observed for the lesions with fiducials placed using FPGS on Wilcoxon rank sum test (p < 0.001). The rate of complication was low and not statistically different between cohorts (p = 0.44).
Conclusions: The FPGS can be used during the deployment of fiducial markers and may increase the number of fiducials tracked.
Trial Registration: An exemption for this retrospective review was granted by the East Carolina University IRB under UMCIRB 15-001726.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6625013 | PMC |
| http://dx.doi.org/10.1186/s13014-019-1306-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Robotic Stereotactic Ablative Radiotherapy for Patients with Early-Stage Lung Cancer: Results of an Interim Analysis.
Cancers (Basel)
September 2024
Department of Clinical Radiation Oncology, Attikon Hospital, School of Medicine, National and Kapodistrian University of Athens, 12462 Athens, Greece.
Article Synopsis
- Surgery is the main treatment for early-stage lung cancer, but for patients who can't undergo surgery, stereotactic ablative radiotherapy (SABR) offers a promising non-invasive option.
- An interim analysis of a trial involving 81 patients treated with SABR showed high local control rates (100%) and minimal side effects, with only 6% experiencing non-significant lung injury.
- The projected survival rates after 24 months were 95% for local progression-free survival and 94% for disease-specific overall survival, indicating SABR's effectiveness for early-stage lung cancer patients.
Is the digital rectal exam any good as a prostate cancer screening test?
Br J Gen Pract
March 2024
Prostate Cancer UK.
Stereotactic ablative radiotherapy for treating primary head and neck cancer and locoregional recurrence: A comprehensive review of the literature.
Clin Transl Radiat Oncol
May 2024
Department of Radiation Oncology, University Hospital Zurich and University of Zurich, Rämistrasse 100, Zurich 8091, Switzerland.
Introduction: Although stereotactic ablative radiotherapy (SABR) has advance to standard-of-care for many different indications like lung and liver malignancies, it still remains in its infancy for treating head and neck cancer. Nevertheless there is a growing body of experience and evidence, which is summarized in this review Methods A thorough search of the literature was performed and critically reviewed both for SABR as a primary treatment as well as for treating locoregionally recurrent disease in a pre-irradiated field.
Results: There exist only few prospective data published so far for treating head and neck cancer with SABR.
Treatment Outcomes of Stereotactic Ablative Body Radiotherapy on Extra-cranial Oligometastatic and Oligoprogressive Breast Cancer: Mature Results from a Single Institution Experience.
Clin Oncol (R Coll Radiol)
June 2024
Mount Vernon Cancer Centre, Northwood, Middlesex, UK; Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, Canada; Department of Radiation Oncology, University of Toronto, Toronto, Canada. Electronic address:
Aims: Evidence shows stereotactic ablative body radiotherapy (SABR) is used as a non-invasive ablative therapy in the treatment of multisite oligometastatic (OM) and oligoprogressive (OP) diseases originating from metastatic breast cancer. This study aims to report the treatment outcomes and to investigate what factors that are prognostic in terms of local control, progression-free survival (PFS) and overall survival (OS) in patients receiving SABR for extracranial OM and OP diseases originating from metastatic breast cancer.
Materials And Methods: A retrospective review on treatment records of patients with OM and OP from metastatic breast cancer who underwent SABR at a single was carried out.
Clinical Factors That Affect Fiducial Tracking in Robotic SABR for Lung Tumors.
Adv Radiat Oncol
May 2023
Department of Radiation Oncology, Brody School of Medicine, East Carolina University, Greenville, North Carolina.
Purpose: SABR is a treatment option for patients with lung tumors that employs fiducials to track tumors during the breathing cycle. Currently, there is a paucity of data on how relative fiducial location and patient clinical characteristics affect fiducial tracking and clinical outcomes. This study aimed to identify factors that reduce the number of fiducials tracked with respiratory motion management during SABR.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!